Global Auto Injector Market Size, Share, Opportunities, And Trends By Type (Disposable Auto-Injectors, Reusable Auto-Injectors), By Application (Rheumatoid Arthritis, Anaphylaxis, Multiple Sclerosis, Others), By End-User (Homecare Settings, Hospitals & Clinics), And By Geography - Forecasts From 2024 To 2029

The global auto-injector market is evaluated at US$69.171 billion for the year 2022 and is projected to grow at a CAGR of 19.39% to reach a market size of US$239.145 billion by the year 2029.

Auto-injectors are syringes accompanied by a spring-charged needle with a pre-charged dosage of drugs or medicine. The convenience and user-friendliness offered by auto-injectors are increasing the demand for auto-injectors over conventional syringes. They are widely preferred over conventional syringes as they reduce anxiety and panic in patients compared to conventional syringes.

 The increasing cases of chronic diseases have boosted the global auto-injector market growth. One of the major factors increasing the popularity and acceptability of auto-injectors over conventional syringes is the reduced anxiety caused by auto-injectors in patients. The pre-charged dosage of drugs in auto-injectors also increases the effectiveness and convenience of auto-injectors for medical practitioners. The percentage of errors reported in auto-injectors is lower than that of conventional syringes.

The significant investments in research and technological developments in medical drug injection by major market players are also contributing to the auto-injector market growth. The rising trend of home-based medical diagnosis and medical care also increases the demand for auto-injectors in the global market. The wide use of auto-injectors for the self-injection of epinephrine to prevent anaphylaxis is also boosting the market growth of auto-injectors as cases of anaphylaxis are increasing.

Market Drivers:

• Rising cases of chronic diseases are anticipated to propel the global auto injector market.

The rising cases of chronic diseases are one of the major factors driving the global auto-injectors market growth. The increasing rate of anaphylaxis cases is also pushing the market growth of auto-injectors, as the drug for the treatment of anaphylaxis is usually self-administered to patients with the help of auto-injectors.

According to the global overview of WAO (World Allergic Organisation), the percentage of anaphylaxis cases is mostly reported in adults compared to children.  Adults or older people affected by anaphylaxis mainly seek the support of self-administered auto-injectors for the dosage intake of drugs like epinephrine. According to PAHO (Pan American Health Organisation), about 2% of the total American population is facing the effects of anaphylaxis.

The rising trend of home-based medical care for lifestyle diseases and others is also fuelling the market growth of auto-injectors compared to conventional syringes. The benefits offered by auto-injectors in self-administration and effectiveness in dosage quantity are pushing the market value of auto-injectors globally.

• Rising investment in companies is expected to surge the market growth.

The significant investments offered by major market players in injectors and self-injectors are giving potential to the global market growth of auto-injectors. The research and developments taking place in drug dosage administration are technically enhancing and developing the sector of auto-injectors.

The support offered by the government in research and development in the medical field is also resulting in the auto-injector market growth. The large investments and involvement of companies like Amgen and Antares Pharma are also leading to enhancement and development in the field of autoinjectors.

The North American region accounted for the largest share.

Geographically, the North American region accounts for the major market share in the global auto-injector market. The increasing cases of anaphylaxis, arthritis, and other diseases in which auto-injectors are widely used are fuelling the market growth of auto-injectors in the North American region. The Asia-Pacific region follows the market growth of the auto-injectors.

North America, particularly the United States and Canada, is a major market for auto-injectors due to its high prevalence of chronic diseases like diabetes, rheumatoid arthritis, and multiple sclerosis. The region's advanced healthcare infrastructure, technological advancements, and regulatory environment contribute to the rapid adoption of these devices. Patient preferences and education, along with economic factors, also influence the demand for auto-injectors.

The region's strong economic strength may lead to higher healthcare spending on advanced medical devices like auto-injectors. The presence of major pharmaceutical and medical device companies headquartered or with a strong presence in North America can further boost the region's market share.

Key Developments:

• May 2023- SHL Medical and MoonLake Immunotherapeutics collaborated to create an autoinjector for MoonLake's Nanobody sonelokimab, a drug designed to target inflammation sites and penetrate inflamed tissues and joints. The Molly autoinjector technology, a modular platform, was used to reduce initial investments and expedite development timelines. SHL Medical will provide device development expertise, assembly guidance, and production competencies to support the sonelokimab drug-device project. MoonLake Immunotherapeutics Chief Technical Officer Oliver Daltrop is excited about the collaboration.
• October 2022- Biocorp and BD partnered to use connected technology to track adherence for self-administered drug therapies, including biologics. Biocorp's Injay technology, which uses Near Field Communication integrated with BD UltraSafe Plus™ Passive Needle Guard for prefillable syringes. The integration aims to improve adherence and outcomes of injectable drugs. The global connected drug delivery market is expected to grow at double-digit rates over the next decade due to shifts from acute care to home care and increased self-administered therapies.
• May 2022- Jabil Healthcare introduced the Qfinity™ autoinjector platform, a reusable and modular solution for subcutaneous drug self-administration at a lower cost than market alternatives. The platform can handle over 100 injections per device and is designed to help patients self-administer various injectables, including larger volume, higher viscosity medicines. It offers a patient-centric form factor and addresses the challenge of medical waste, as plastic disposable syringes generate the highest percentage of medical-grade plastic waste. The Qfinity+ autoinjector also offers a connected version for remote monitoring.
• May 2022- Stevanato Group partnered with Owen Mumford Ltd. to manufacture the Aidaptus® auto-injector platform, offering pharmaceutical customers a full range of capabilities. The partnership involved Stevanato Group molding components, providing final and sub-assembly equipment, and offering market-leading pre-filled syringes. Assembly carried out by both Stevanato Group and Owen Mumford at their UK automated assembly center. The collaboration aims to streamline device production and deliver the full value of the Aidaptus® platform, which is a versatile 2-step, single-use auto-injector that accommodates both 1mL and 2.25 mL prefilled glass syringes.

Market Segmentation:

• By Type
  • Disposable autoinjectors
  • Reusable autoinjectors
• By Application
  • Rheumatoid Arthritis 
  • Anaphylaxis
  • Multiple sclerosis
  • Others
• By End-user
  • Homecare settings
  • Hospitals & Clinics
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • UK
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others